Physician profile
Amanda L Atha
NPI 1114356490
$6,021.30
in general payments reported to CMS, 2019-2025
25 companies · $3,398 in 2025
The $3,398 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,623 · 2025: $3,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,343 · Education: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,342.82 |
| Education | $678.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $825.07 | 2024-2025 | |
| Janssen Biotech, INC. | $702.09 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $673.70 | 2024-2025 | |
| Genzyme Corporation | $600.35 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $481.18 | 2024-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $456.54 | 2024-2025 | |
| Amgen INC. | $389.07 | 2024-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $323.69 | 2024-2025 | Dupixent, Libtayo |
| Incyte Corporation | $255.21 | 2024-2025 | Opzelura |
| Ucb, INC. | $233.39 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $188.58 | 2024-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $167.01 | 2024-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $152.47 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $125.09 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $72.23 | 2024-2025 | Taltz, Ebglyss, Olumiant |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $71.08 | 2025 | Vtama |
| Pfizer INC. | $66.03 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.99 | 2024-2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $38.26 | 2024-2025 | Ycanth |
| Journey Medical Corporation | $36.60 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $32.51 | 2025 | |
| Mimedx Group, INC. | $22.31 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.30 | 2025 | Cabtreo |
| Botanix Sb INC | $20.00 | 2025 | Sofdra |
| Lnhc, INC | $19.55 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Atha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.